NCT05290337View on ClinicalTrials.gov

ZR-CHOP in DLBCL With Specific Gene Abnormality

PHASE2RecruitingINTERVENTIONAL

Enrollment

62

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2026

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

zanubrutinib

BTK inhibitor

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER